Relay To Take On AstraZeneca With RLY-2608 In PI3Kα-Mutated Breast Cancer

The firm is planning a head-to-head trial against AstraZeneca’s Truqap after RLY-2608 showed better safety and efficacy in a Phase I trial, including a four-month PFS benefit.

• Source: Shutterstock

AstraZeneca PLC’s PI3Kα inhibitor Truqap (capivasertib) won US Food and Drug Administration approval late last year and has quickly become the standard of care in certain patients with breast cancer, but could soon face a challenger in the form of Relay Therapeutics, Inc.’s RLY-2608, which has shown strong results in a Phase I clinical trial.

Cambridge, MA-based Relay announced interim results on 9 September from the study of RLY-2608 – an allosteric, pan-mutant and isoform-selective...

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.